Azar’s socialist price controls put Americans patients last
By Stacy Washington
President Trump thinks Americans pay too much for prescription drugs and says foreign countries are to blame. In a speech, he criticized nations that use socialist price controls to artificially hold down the cost of pharmaceuticals. “For decades,” he noted, “other countries have rigged the system so that American patients are charged much more … for the exact same drug.”
The president’s criticism is spot on. That’s why a new initiative from his Department of Health and Human Services is so shocking. HHS Secretary Alex Azar just proposed a major overhaul of Medicare that would impose those socialist price controls here in the United States.
Instead of putting America first and forcing other countries to play by the rules, the proposal legitimizes foreign freeloading. The price controls would limit seniors’ access to lifesaving drugs and chill pharmaceutical research efforts.
President Trump correctly notes that prescription drugs are more expensive in America. The reason for the price disparity is simple. Nations with socialized medicine including Canada, the United Kingdom, and France cap prescription prices. If a drug is too expensive, the government won’t offer it to patients.
Once drug companies have developed a medicine, they have a limited amount of time to sell it and recoup their costs before the patent expires. So it makes sense for American drug companies to market their products in price-controlled nations, even if that means granting steep discounts. The alternative is earning no foreign revenue at all.
As a result, American patients fund the lion’s share of global research and development costs. The HHS proposal wouldn’t rectify this injustice; it would only further harm American patients.
Right now, Medicare drug payments are based on each medicine’s average domestic sales price. Sec. Azar wants to instead index Medicare payments to the average prices paid in 14 other countries.
Copying other nation’s socialist price controls would reduce American patients’ access to the latest medicines.
Consider treatments for respiratory conditions. All new respiratory drugs released globally in the last seven years are available to Americans. Patients in Japan and France, two of the reference countries included in Sec. Azar’s pricing index, can only access 55 percent of those medicines.
Domestic price controls would also smother drug innovation, depriving future patients of potentially lifesaving cures.
Europe is a cautionary tale. The region led the world in biopharmaceutical R&D investment in the 1980s. But once several nations adopted price control policies, Europe suffered a dramatic decline in research investment. Today, the United States spends 40 percent more on biopharmaceutical R&D than Europe.
Sec. Azar’s proposal would reward the forces of socialism abroad and threaten American ingenuity and prosperity at home. Patients can only hope that President Trump orders his HHS secretary to scrap the plan.
Stacy Washington is a decorated Air Force Veteran, an Emmy-nominated TV personality, and the host of the nationally syndicated radio program “Stacy on the Right.”
The viewpoints expressed above are those of the author and do not necessarily reflect those of The Independent.
How to submit an article, guest opinion piece, or letter to the editor to The Independent
Do you have something to say? Want your voice to be heard by thousands of readers? Send The Independent your letter to the editor or guest opinion piece. All submissions will be considered for publication by our editorial staff. If your letter or editorial is accepted, it will run on suindependent.com, and we’ll promote it through all of our social media channels. We may even decide to include it in our monthly print edition. Just follow our simple submission guidelines and make your voice heard:
—Submissions should be between 300 and 1,500 words.
—Submissions must be sent to editor@infowest.com as a .doc, .docx, .txt, or .rtf file.
—The subject line of the email containing your submission should read “Letter to the editor.”
—Attach your name to both the email and the document file (we don’t run anonymous letters).
—If you have a photo or image you’d like us to use and it’s in .jpg format, at least 1200 X 754 pixels large, and your intellectual property (you own the copyright), feel free to attach it as well, though we reserve the right to choose a different image.
—If you are on Twitter and would like a shout-out when your piece or letter is published, include that in your correspondence and we’ll give you a mention at the time of publication.
